Implantation of cardiac progenitor cells using self-assembling peptide improves cardiac function after myocardial infarction.
Implantation of various types of cells into the heart has been reported to be effective for heart failure, however, it is unknown what kinds of cells are most suitable for myocardial repair. To examine which types of cells are most effective, we injected cell-Puramatrix™ (PM) complex into the border area and overlaid the cell-PM patch on the myocardial infarction (MI) area. We compared cardiac morphology and function at 2 weeks after transplantation. Among clonal stem cell antigen-1 positive cardiac progenitors with PM (cSca-1/PM), bone marrow mononuclear cells with PM (BM/PM), skeletal myoblasts with PM (SM/PM), adipose tissue-derived mesenchymal cells with PM (AMC/PM), PM alone (PM), and non-treated MI group (MI), the infarct area of cSca-1/PM was smaller than that of BM/PM, SM/PM, PM and MI. cSca-1/PM and AMC/PM attenuated ventricular enlargement and restored cardiac function in comparison with MI. Capillary density in the infarct area of cSca-1/PM was higher than that of other five groups. The percentage of TUNEL positive cardiomyocytes in the infarct area of cSca-1/PM was lower than that of MI and PM. cSca-1 secreted VEGF and some of them differentiated into cardiomyocytes and vascular smooth muscle cells. These results suggest that transplantation of cSca-1/PM most effectively prevents cardiac remodeling and dysfunction through angiogenesis, inhibition of apoptosis and myocardial regeneration.
Tokunaga
Masakuni
M
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Liu
Mei-Lan
ML
Nagai
Toshio
T
Iwanaga
Koji
K
Matsuura
Katsuhisa
K
Takahashi
Toshinao
T
Kanda
Masato
M
Kondo
Naomichi
N
Wang
Pin
P
Naito
Atsuhiko T
AT
Komuro
Issei
I
D000199:Actins / Q000378:metabolism; D043925:Angiogenesis Inducing Agents / Q000378:metabolism; D000818:Animals; D000950:Antigens, Ly / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D002196:Capillaries / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002460:Cell Line; D054338:Cell Transdifferentiation / Q000187:drug effects; D006334:Heart Function Tests / Q000187:drug effects*; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D009206:Myocardium / Q000166:cytology*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000473:pathology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology*; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects; D013599:Systole / Q000187:drug effects; D014463:Ultrasonography; D020257:Ventricular Remodeling / Q000187:drug effects; D014841:von Willebrand Factor / Q000378:metabolism
D000199:Actins; D043925:Angiogenesis Inducing Agents; D000950:Antigens, Ly; C074650:Ly6a protein, mouse; D008565:Membrane Proteins; D010455:Peptides; C546681:RADA16-I; D014841:von Willebrand Factor